Mantra Capital (511577)
TurnaroundScore breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹21.75 |
| Market Cap | ₹68.73 Cr |
| P/E Ratio | 0 |
| ROCE | -36.86% |
| ROE | -35.47% |
| Dividend Yield | 0% |
| Profit Growth | -59.38% |
| Debt/Equity | — |
| Sales Growth | 528.57% |
| 52-Week Range | ₹12.48 — ₹21.75 |
| Sector | Finance |
| Book Value | ₹11.56 |
Strengths
- Sales growth of 528.57% shows expanding business activity.
- Book value of ₹11.56 per share provides some tangible asset backing.
- Latest quarter sales of ₹5 Cr gives a small but real revenue base.
- Small market cap of ₹69 Cr offers potential upside if a genuine turnaround occurs.
Concerns
- Persistent losses: latest quarterly net profit is -₹3 Cr, with ROE at -35.47% and ROCE at -36.86%.
- Piotroski F-Score of 3/9 indicates weak underlying financial health.
- Stock trades at ₹21.75, a 1.88x premium to book value, despite zero earnings and no dividend.
- Critical data missing: promoter holding and debt/equity are N/A, limiting transparency and trust.
AI Analysis
At first glance, Mantra Capital looks like the kind of small NBFC that would make me very cautious. The market cap is just ₹69 Cr, and the latest quarter shows sales of ₹5 Cr but a net loss of ₹3 Cr. That is not a business creating value; it is burning capital. ROE is -35.47% and ROCE is -36.86%, meaning every rupee of equity and capital employed is being eroded. Graham would ask: where is the margin of safety? The book value is ₹11.56 per share, yet the stock trades at ₹21.75, a P/B of 1.88. Paying almost twice book for a company with no earnings and negative returns is speculation, not investment. The 528.57% sales growth catches the eye, but as Buffett says, sales growth without profits is like water flowing into a leaky bucket. Profit growth of -59.38% and a Piotroski F-Score of 3 out of 9 confirm the financial health is weak. I also have no promoter holding data, no debt/equity ratio, and a P/E of zero—meaning I cannot even use earnings to value it. This is not a fast grower; a fast grower compounds profits. This is a possible turnaround, but only if management can stop the bleeding and convert revenue into earnings. Until then, the sane move is to watch from the sidelines. I need evidence of cost discipline, improved margins, and sane capital allocation before I even consider paying ₹21.75 for this. In Graham's words, price is what you pay, value is what you get. Here, I see no clear value.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer